Pyrimidine, pyrimidone compound, and medical compound and application thereof
A technology of ketone compounds and pyrimidines, which is applied in drug combination, organic chemistry, antineoplastic drugs, etc., can solve the problems that cannot solve the clinical pressure of drug resistance, toxic side effects of wild-type cells, poor selectivity, etc.
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0129] N-(3-(3-methyl-7-(methylamino)-2-oxo-3,4-dihydropyrimidin[4,5-d]pyrimidine-1(2hydro)-substituted)phenyl)propene Amide (C-EGF21)
[0130] (N-(3-(3-methyl-7-(methylamino)-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide)
[0131]
[0132] Step 1. 4-(3-tert-butoxycarbonylaminoaniline)-2-methylmercaptopyrimidine-5-ethyl carbonate
[0133] (ethyl 4-(3-(tert-butoxycarbonylamino)phenylamino)-2-(methylthio)pyrimidine-5-carboxylate)
[0134]
[0135] 4-Chloro-2-methylmercaptopyrimidine-5-ethyl carbonate (23.3g, 100mmol), N-Boc m-phenylenediamine (20.8g, 1.0eq), K 2 CO 3 (27.6g, 2.0eq) was dissolved in 300ml of anhydrous DMF, heated to 80°C under nitrogen protection, and stirred overnight. After cooling to room temperature, 1000 ml of ice water was added with stirring, and a large amount of solids precipitated out. It was filtered under reduced pressure and dried in vacuo to obtain 38.8 g (96%) of a white solid.
[0136] 1 H NMR (400Hz, CDCl 3 )δ...
Embodiment 2
[0174] N-(3-(3-methyl-2-oxo-7-(anilino)-3,4-dihydropyrimidin[4,5-d]pyrimidine-1(2hydro)-substituted)phenyl)propene Amide (C-EGF10)
[0175] N-(3-(3-methyl-2-oxo-7-(phenylamino)-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide
[0176]
[0177] The synthesis method is as in Example 1.
[0178] 1 H NMR (400Hz, DMSO-d 6)δ10.30(s, 1H), 9.41(s, 1H), 8.18(s, 1H), 7.43(d, J=8.0Hz, 1H), 7.66(s, 1H), 7.45(t, J=8.0 Hz, 1H), 7.27(d, J=8.0Hz, 2H), 6.99(d, J=8.0Hz, 1H), 6.93(t, J=7.6Hz, 2H), 6.75(t, J=7.2Hz, 1H), 6.42(dd, J=10.4, 16.8Hz, 1H), 6.24(d, J=16.8Hz, 1H), 5.75(d, J=10.4Hz, 1H), 4.48(s, 2H), 2.97( s, 3H).
[0179] LCMS(ESI): m / z 401.1[M+H] + .
Embodiment 3
[0181] N-(3-(3-methyl-7-(4-methylpiperazine-1-substituted)-2-oxo-3,4-dihydropyrimidine[4,5-d]pyrimidine-1(2hydro )-substituted)phenyl)acrylamide (C-EGF19)
[0182] N-(3-(3-methyl-7-(4-methylpiperazin-1-yl)-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)phenyl)acrylamide
[0183]
[0184] The synthesis method is as in Example 1.
[0185] 1 H NMR (400Hz, DMSO-d 6 )δ8.25(s, 1H), 7.95(s, 1H), 7.53(s, 1H), 7.38(d, J=7.6Hz, 1H), 7.23-7.27(m, 1H), 6.88(d, J =7.6Hz, 1H), 6.32(d, J=16.4Hz, 1H), 6.12(dd, J=10.0, 16.4Hz, 1H), 5.64(d, J=10.0Hz, 1H), 4.41(s, 2H ), 3.52(m, 4H), 3.10(s, 3H), 2.30(m, 4H), 2.25(s, 3H).LCMS(ESI): m / z 408.2[M+H] + .
PUM

Abstract
Description
Claims
Application Information

- Generate Ideas
- Intellectual Property
- Life Sciences
- Materials
- Tech Scout
- Unparalleled Data Quality
- Higher Quality Content
- 60% Fewer Hallucinations
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com